Acute gefitinib-induced pneumonitis.
A 60-year-old woman with non-small cell lung cancer was treated with gefitinib and developed acute pneumonitis on the third day. Pulmonary damage and/or interstitial lung disease (ILD) related to gefitinib was diagnosed clinically and radiographically. Despite the immediate withdrawal of gefitinib and the administration of high-dose steroid, the patient did not fully recover and finally died of respiratory failure on day 22 after gefitinib had commenced. This case cautions us that careful monitoring provides no guarantee of safeguarding patients against ILD caused by gefitinib. We should make the decision to treat patients with gefitinib very carefully until we can elucidate which patients are at high risk and which patients are likely to have a response to this drug.
Ohyanagi
Fumiyoshi
F
Department of Clinical Oncology, Saitama Medical School, 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama 350-0451, Japan.
Ando
Yuichi
Y
Nagashima
Fumio
F
Narabayashi
Masaru
M
Sasaki
Yasutsuna
Y
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D017809:Fatal Outcome; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D011014:Pneumonia / Q000139:chemically induced*; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D012131:Respiratory Insufficiency
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib